CJC-1293 (CJC-1295 w/o DAC , Mod GRF 1-29 ) is a Growth Hormone Releasing Hormone. It exerts its effects on the Ghrelin receptor inducing the release of GH and a corresponding increase in IGF as well.
The history of this peptide is an interesting one. It was actually first produced strictly for comparison purposes to CJC-1295. There was not thought to be any research value to this compound, it was strictly to be used as a comparative tool. How ironic something synthesized for the above purpose, has become so widely accepted and such a valuable tool in our research.
In Vivo GHRH similar to CJC-1293 is released from the hypothalamus and then goes on to stimulate the Ghrelin Receptor. In our research the introduction of peptide CJC-1293 exhibits the same effect on these receptors. Eliciting the GH release often desired in our research.
What makes CJC-1293 different from its predecessor, CJC-1295, is the removal of the DAC which has shortened the half-life considerably. This peptide exerts its effects for approximately 30 mins.
Many researchers prefer the short, pulse type release of GH and IGF that CJC-1293 provides. Much like CJC-1295 the GH and IGF increase is well above normal physiological levels, something often desired in our research.
This product definitely has proven to have its place in our research circles.
Refs:
* Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP (2005). "Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog". Endocrinology 146 (7): 3052–8. doi:10.1210/en.2004-1286. PMID 15817669
* Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus, Frohman LA, J Clin Invest. 1986 78:906–913